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e18Introduction: Dapoxetine is a short-acting selective serotonin reuptake inhibitor for treatment of premature
ejaculation (PE).
Aim: To evaluate the efﬁcacy and safety of dapoxetine 30 and 60 mg as needed in Asia-Paciﬁc men with PE.
Methods: The study was a prospective, 12-week, open-label study to evaluate the efﬁcacy and safety of ﬂexible-
dose dapoxetine in men with PE diagnosed by a Premature Ejaculation Diagnostic Tool score of at least 11, a
self-estimated intravaginal ejaculation latency time (IELT) no longer than 2 minutes, and an International Index
of Erectile Function erectile function domain score of at least 21.
Main Outcome Measures: Percentage of subjects reporting their PE as at least “slightly better” using the
Clinical Global Impression of Change (CGIC) question.
Results: Two hundred eighteen of 285 randomized subjects completed the study. The mean subject age was
45.9 years and 57.7% were Korean. Dosages 1 (30 mg), 2 (30/ 60 mg), and 3 (30/ 60/ 30 mg) were used
in 141, 124, and 13 subjects, respectively. At study end, a PE CGIC rating of at least “slightly better” was
reported by 77.3%, 92.8%, and 100% of subjects for dosages 1, 2, and 3, respectively (P ¼ .49). At study end, a
CGIC rating of “slightly better” was reported by 85.2% and 85.3% of subjects with lifelong PE and acquired PE,
respectively (P ¼ .50). At study end, a CGIC rating of “slightly better” was reported by 84.1% and 86.4% of
subjects with an estimated baseline IELT no longer than and at least 1 minute, respectively (P ¼ .16). The
incidence of a CGIC rating of at least “slightly better” was lower in subjects reporting an adverse event of
moderate or severe severity and in subjects who increased to and maintained a dapoxetine dose of 60 mg and
higher in subjects older than 50 years and in subjects with a baseline estimated IELT of at least 1 minute.
Conclusion: In this study, ﬂexible dosing of dapoxetine (30 and 60 mg) appeared effective in the treatment of PE.
Sex Med 2016;4:e18ee27. Copyright  2016, The Authors. Published by Elsevier Inc. on behalf of the International
Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Premature ejaculation (PE) is a common male sexual disorder
associated with a substantial personal and interpersonal negative
psychological burden.1e4 During the past 20 to 30 years, the
PE treatment paradigm, previously limited to behavioral psycho-
therapy, has expanded to include drug treatment.5e7 Animal and
human sexual psychopharmacologic studies have found that se-
rotonin (5-hydroxy-tryptamine) and its receptors are involved in
ejaculation and have conﬁrmed a role for selective serotonin re-
uptake inhibitors (SSRIs) in the treatment of PE.8e10 Multiple
well-controlled evidence-based studies have reported on the efﬁ-
cacy and safety of SSRIs in delaying ejaculation, conﬁrming their
role as ﬁrst-line agents for the treatment of lifelong and acquired
PE.11 More recently, there has been increased attention to theSex Med 2016;4:e18ee27
The PASSION Study e19psychosocial consequences of PE, its epidemiology, its etiology,
and its pathophysiology by clinicians and the pharmaceutical
industry.1,2,12e15
Dapoxetine (Priligy, Menarini Industrie Farmaceutiche
Riunite Srl, Florence, Italy) is the ﬁrst compound speciﬁcally
developed for the treatment of PE. Dapoxetine is a potent SSRI
that undergoes rapid absorption and elimination, resulting in
minimal accumulation, and has dose-proportional pharmacoki-
netics that are unaffected by multiple dosing and do not vary
among ethnic groups.16e18
The results of two phase 2 and seven phase 3 trials have been
published.19e26 All were conducted before the development
of the International Society for Sexual Medicine deﬁnitions
of PE27,28 and instead used Diagnostic and Statistical Manual
of Mental Disorder, Fourth Edition criteria and a baseline intra-
vaginal ejaculation latency time (IELT) no longer than 2 minutes
on 75% of at least four sexual intercourse events as inclusion
criteria. An analysis of pooled phase 3 data conﬁrmed that
dapoxetine 30 and 60 mg increased IELTs and improved
patient-reported outcomes (PROs) of control, ejaculation-related
distress, interpersonal distress, and sexual satisfaction compared
with placebo.29 Efﬁcacy results were similar across the individual
trials, indicating that dapoxetine is consistently more efﬁcacious
than placebo regardless of a subject’s demographic characteristics.
Across trials, dapoxetine 30 and 60 mg were well tolerated with a
low incidence of severe adverse effects. The most frequently re-
ported adverse events (AEs) were nausea, diarrhea, headache,
dizziness, insomnia, somnolence, fatigue, and nasopharyngitis.
There are several PE intervention outcome measurements.
The Clinical Global Impression of Change (CGIC) is a simple,
brief, validated, patient-reported single-question scale used to
assess the response of PE to treatment as much worse,” “worse,”
“slightly worse,” “no change,” “slightly better,” “better,” or
“much better.” Althof et al30 reported that the CGIC is a valid
measurement in men with PE and provides clinicians with a valid
and brief outcome assessment of their patient’s condition.
The primary objective of this study was to measure the per-
centage of subjects with PE who reported their PE as at least
slightly better using the CGIC question after 12 weeks of
treatment with ﬂexible dosing of dapoxetine (30 and 60 mg).METHODS
The study was a prospective, observational study to evaluate the
efﬁcacy and safety of ﬂexible-dose on-demand dapoxetine admin-
istered 1 to 3 hours before planned sexual intercourse at a starting
dose of 30 mg that could be increased to 60 mg if the response was
insufﬁcient and the side effects were acceptable. The total study
duration was 16 weeks, comprising a 2-week pretreatment phase
and a 12-week open-label treatment phase, followed by a telephone
contact 2 weeks after week 12 to follow up on AEs. The study was
conducted at 23 sites in three countries. Therewere 13 sites in South
Korea, 5 sites in Australia, and 5 sites in Thailand.Sex Med 2016;4:e18ee27Inclusion and Exclusion Criteria
The study population was comprised of subjects with PE who
were heterosexual men, at least 18 years old, were in a stable
monogamous sexual relationship with a woman for at least 6
months, scored at least 11 on the Premature Ejaculation Diag-
nostic Tool (PEDT), reported a self-estimated IELT no longer
than 2 minutes, had an International Index of Erectile Function
(IIEF) erectile function domain score of at least 21, had PE that
was not due exclusively to the direct effects of a substance, were
in good general health, had systolic and diastolic blood pressures
of 180 and 100 mmHg, respectively, at screening and at the
baseline visit, and whose partner was not pregnant at screening.
Subjects who had speciﬁed conditions related to the urogenital,
sexual, endocrine, cardiovascular, metabolic and psychiatric sys-
tems or abnormal laboratory ﬁndings or received speciﬁed
medications were excluded from participating in the study. A
washout period of 30 days was required for subjects previously
treated with an off-label antidepressant drug.
Study Efﬁcacy End Points
Primary Efﬁcacy End Point
The primary end point was the dapoxetine response rate with
95% CI expressed as the percentage of subjects who reported their
PE as at least slightly better using the CGIC question after 12 weeks
of treatment with ﬂexible dosing of dapoxetine (30 and 60 mg).Secondary Efﬁcacy End Points
The following secondary end points were evaluated using the
Premature Ejaculation Proﬁle (PEP) for subjects and their part-
ners who opted to participate in the study, at baseline, and at
weeks 4, 8, and 12: control over ejaculation, satisfaction with
sexual intercourse, personal distress, interpersonal difﬁculty, and
CGIC rating. The PEP is a validated, self-reported outcome
instrument comprised of four single-item measurements, a
response proﬁle, and an index score for evaluating the domains of
PE and response to treatment.31
Study Overview
At visit 1 (screening), eligibility for enrollment in the study
was contingent upon the diagnosis of PE with a PEDT score
of at least 11, a self-estimated average IELT no longer than 2
minutes during the previous 4 weeks, and the absence of mod-
erate to severe erectile dysfunction with a combined score of at
least 21 for the erectile function domain of the IIEF. The PEDT
is a ﬁve-item, multidimensional, psychometrically, and linguis-
tically validated instrument for diagnosing PE, which captures
the elements of control, frequency, minimal stimulation, distress,
and interpersonal difﬁculty.32e34 The IIEF is a 15-item, self-
administered questionnaire that can assess the presence and
severity of erectile dysfunction.35
In addition, subjects with but not limited to the following con-
ditionswere ineligible for the study: hypoactive sexual desire, known
or suspected hypogonadism, hyperprolactinemia or untreated or
e20 McMahon et alinsufﬁciently treated hypothyroidism, signiﬁcant cardiovascular
disease with a cerebrovascular accident or myocardial infarction
within the previous 6 months, a history of or current major psy-
chiatric disorder or depression, current use or failure to complete the
required washout period for SSRI or serotonin and norepinephrine
reuptake inhibitor compounds, previous exposure to dapoxetine
or a partner who was pregnant, planning to become pregnant,
breastfeeding, or had signiﬁcant female sexual dysfunction.
During the subsequent 2-week pretreatment period, subjects
and their partners were required to attempt sexual intercourse at
least two times and to complete a baseline event log to reconﬁrm
eligibility for enrollment at visit 2 (baseline). At visit 2 (baseline),
subjects and consented partners completed the PEP.
At visit 2 (baseline), eligible subjects were given study medi-
cation (dapoxetine 30 mg) and a treatment log to complete at
each dosing. The subject was instructed to take one tablet of
dapoxetine 30 mg, as needed, 1 to 3 hours before sexual activity.
At visits 3 (week 4) and 4 (week 8), subject treatment logs,
occurrence of AEs, and new concomitant therapy use were
monitored and dose titration (30 to 60 mg) was conducted for
subjects who had used and tolerated dapoxetine 30 mg at least
four times and wanted a better treatment outcome. In addition,
at visit 4 (week), subjects previously up-titrated to 60 mg who
had used and not tolerated dapoxetine 60 mg for at least one
time were down-titrated to 30 mg. At visits 3 (week 4) and 4
(week 8), subjects and their partners were asked to complete the
CGIC question and the PEP.
At visit 5 (week 12, ﬁnal visit or early termination), subjects
and their partners were asked to complete the CGIC question
and the PEP. A telephone contact 2 weeks after the ﬁnal visit or
early termination was conducted to follow up on reported AEs.
Safety Assessments
Safety and tolerability were evaluated throughout the study by
examining the incidence, severity, and type of AEs and serious AEs,
clinical laboratory results, 12-lead electrocardiogram, vital sign
measurements, and physical examination results. If, during the
study, a subject developed signs or symptoms consistent with
syncope, then additional details were collected and reported. Each
subject who reported an AE was followed until the AE resolved.
Statistical Analysis
Sample Size
Sample size was calculated as 285 subjects based on the
response rate of subjects reporting a CGIC rating of at least
slightly better in previous dapoxetine studies and an expected
dropout rate of 15% to achieve a precision of 5% of half-width of
95% CI for the true response rate.
Efﬁcacy Analysis
Descriptive statistics with 95% CIs were used to summarize
the efﬁcacy of dapoxetine primary and secondary end points.Subgroup analysis was conducted and deﬁned by the following
factors.
1. Dapoxetine dose
a. Subjects who remained on dapoxetine 30 mg until the end
of the study (dosage 1)
b. Subjects who up-titrated to dapoxetine 60 mg because of
an insufﬁcient response and remained on 60 mg until the
end of the study (dosage 2)
c. Subjects who up-titrated to dapoxetine 60 mg because of
an insufﬁcient response and subsequently down-titrated to
30 mg owing to intolerable adverse effects (dosage 3)
2. Type of PE
a. Subjects with lifelong PE
b. Subjects with acquired PE
The dapoxetine response rate with 95% CI for these sub-
groups was calculated using the Cochran-Mantel-Haenszel c2
test for intergroup comparison. Frequencies and proportions
for each response category for control over ejaculation, satis-
faction with sexual intercourse, personal distress, interpersonal
difﬁculty, and CGIC items for subjects and their partners
were calculated using rank-sum testing to determine the dif-
ference in each secondary end point between subgroups if
appropriate.
This study was conducted in accordance with the ethical
principles originating in the Declaration of Helsinki, good
clinical practices, and all applicable laws and regulations. The
institutional review board or ethics committee at each site
approved the study, and all men provided written informed
consent before undergoing any study procedure or receiving
any study therapy. An independent data monitoring com-
mittee monitored the safety and efﬁcacy of subjects during
the study, and an independent external statistics reporting
group conducted one interim analysis during the course of
the study.RESULTS
In total, 285 subjects were enrolled in the study. Two
hundred eighteen of 285 subjects (76.5%) completed the study
and 67 of 285 subjects (23.5%) discontinued the study
including four subjects who did not take the study drug. The
most frequent reasons for discontinuation were withdrawn
consent (23, 8.1%) and loss to follow-up (21, 7.4%). The mean
age of all subjects was 45.9 years, and most subjects were
Korean (n ¼ 162, 57.65%), Thai (n ¼ 60, 22.42%), and
Caucasian (n ¼ 49, 17.44%; Table 1). One hundred forty-one
subjects were treated with dosage 1 (30 mg), 124 with dosage 2
(30 / 60 mg), and 13 with dosage 3 (30 / 60 / 30;
Table 2). Of the 137 subjects whose dosage was increased from
30 to 60 mg, 11 subsequently decreased to 30 mg, generally
because of decreased tolerability (n ¼ 9 of 11) and 2 decreased
because greater efﬁcacy with the 60-mg dose was not
appreciated.Sex Med 2016;4:e18ee27
Table 1. Patients’ Demographic Characteristics (Subgroups by Dosage)
Dosage 1 ¼ 30 mg
(n ¼ 141)
Dosage 2 ¼ 30/ 60 mg
(n ¼ 124)
Dosage 3 ¼ 30/ 60/ 30 mg
(n ¼ 13) P value
Total
(n ¼ 281)
Age (y)
Mean ± SD 45.5 ± 10.43 46.9 ± 10.47 41.1 ± 7.77 NS 45.9 ± 10.39
Median 46 48 41 47
Range 23e68 21e69 28e53 21e69
Age group, n (%) 144 124 13 281
18e29 7 (4.86) 5 (4.03) 1 (7.69) 13 (4.63)
30e39 35 (24.31) 27 (21.77) 3 (23.08) 65 (23.13)
40e49 44 (30.56) 32 (25.81) 7 (53.85) 83 (29.54)
50e64 56 (38.89) 57 (45.97) 2 (15.38) 115 (40.93)
>65 2 (1.39) 3 (2.42) 0 (0.00) 5 (1.78)
Weight (kg),
mean ± SD
72.29 ± 10.80 75.46 ± 12.79 71.9 ± 12.80 NS 73.67 ± 11.87
BMI
Mean ± SD 24.69 ± 2.79 25.33 ± 3.20 23.90 ± 2.78 24.94 ± 3.0
Median 24 24.76 24.52 24.49
Ethnicity, n (%) 144 124 13 281
Chinese 1 (0.69) 0 (0.00) 0 (0.00) 1 (0.36)
Indian 0 (0.00) 4 (3.23) 0 (0.00) 4 (1.42)
Thai 44 (30.56) 12 (9.68) 7 (53.85) 63 (22.42)
White 12 (8.33) 33 (26.61) 4 (30.77) 49 (17.44)
Korean 85 (59.03) 75 (60.48) 2 (15.38) 162 (57.65)
Other 2 (1.39) 0 (0.00) 0 (0.00) 2 (0.71)
BMI ¼ body mass index; NS ¼ not signiﬁcant.
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Primary End Point
At study end, the proportion of subjects who CGIC rated
their PE as at least slightly better was 77.3% for dosage 1, 92.8%
for dosage 2, and 100% for dosage 3 (P ¼ .49; Table 3).
Secondary End Points
Response to CGIC. At study end, the proportion of subjectswho
rated their PE as at least better using CGIC was 54.6% for dosage 1,
56.5% for dosage 2, and 46.2% for dosage 3 (P ¼ .17; Table 3).
Table 2. Dosing Titration Patterns for Enrolled Subjects
Dosage group Dosing titration pattern (n ¼ 278) n (%)
Dosage 1
(n ¼ 141)
30/ x mg* 30 (10.8)
30/ 30/ x mg 15 (5.4)
30/ 30/ 30 mg* 96 (24.5)
Dosage 2
(n ¼ 124)
30/ 30/ 60 mg 19 (6.9)
30/ 60/ x mg 9 (3.2)
30/ 60/ 60 mg† 96 (34.5)
Dosage 3
(n ¼ 13)
30/ 60/ 30 mg 13 (4.7)
x ¼ unknown dose of dapoxetine because of early withdrawal of subject.
*Includes subjects who withdrew early but took only 30 mg.
†Includes subjectswhowithdrewearlyandwhosedoseescalated to60mg.
Sex Med 2016;4:e18ee27At study end, a PECGIC rating of slightly better, better, andmuch
better was reported by 94 (36.6%), 101 (39.3%), and 33 (12.8%)
subjects, respectively. Fewer than 12% of subjects described their PE
as unchanged or worse (ie, slightly worse, worse, or much worse).
Of the subjects treated with dosage 1, 2, or 3, approximately
75% to 90% CGIC rated their PE as at least slightly better at
visits 3, 4, and 5 (Table 3), whereas approximately 32% to 52%
rated their PE as at least better at visits 3, 4, and 5 (Table 3).
Of subjects with lifelong PE, 85.2% CGIC rated their PE as
slightly better, whereas 85.3% of subjects with acquired PE rated
their PE as slightly better at the ﬁnal visit (P ¼ .50). Of subjects
with an estimated baseline IELT no longer than 1 minute,
84.1% CGIC rated their PE as slightly better, whereas 86.4% of
subjects with an estimated baseline IELT longer than 1 minute
described their PE as slightly better at the ﬁnal visit (P ¼ .16).
Control over ejaculation. Overall, 49.6%, 53.2%, and
53.9% of subjects treated with dosages 1, 2, and 3, respectively,
were observed to achieve a composite end point comprising an at
least two-category improvement in control over ejaculation and
an at least one-category decrease in distress related to ejaculation
at the ﬁnal visit (P ¼ .93; Table 4).
Of subjects with lifelong and acquired PE, 56.5% and 47.9%
of subjects, respectively, achieved the composite end point at
study end (P ¼ .80). Of those subjects with a baseline estimated
IELT no longer than 1 minute, 57.3% achieved the composite
Table 3. “At Least Slightly Better”and “At Least Better Response” Status in Clinical Global Impression of Change in Premature Ejaculation
by Study Visit (Subgroups by Dosage)
Dosage 1 ¼ 30 mg
(n ¼ 141)
Dosage 2 ¼ 30
/ 60 mg (n ¼ 124)
Dosage 3 ¼ 30
/ 60/ 30 mg (n ¼ 13)
Total
(n ¼ 281)
P
value
Visit 3 (week 4)
At least “slightly
better,” n (%)
97 (87.39) 80 (65.04) 11 (84.62) 188 (76.11) .0003
95% CI 79.74e92.93 55.92e73.42 54.55e98.08 70.30e81.29
At least “better,” n (%) 51 (45.95) 24 (19.51) 4 (30.77) 79 (31.98) <.0001
95% CI 36.45e55.67 12.92e27.63 9.09e61.43 26.21e38.19
No change or worse,
n (%)
14 (12.61) 43 (34.96) 2 (15.38) 59 (23.89)
Visit 4 (week 8)
At least slightly
“better,” n (%)
102 (91.89) 111 (89.52) 12 (92.31) 225 (90.73) .8058
95% CI 85.17e96.23 82.74e94.30 63.97e99.81 86.41e94.03
At least “better,” n (%) 56 (50.45) 43 (34.68) 5 (38.46) 104 (41.94) .0491
95% CI 40.80e60.08 26.36e43.75 13.86e68.42 35.72e48.34
No change or worse,
n (%)
9 (8.11) 13 (10.48) 1 (7.69) 23 (9.27)
Visit 5 (week 12)
At least “slightly
better,” n (%)
109 (90.83) 107 (86.29) 12 (92.31) 228 (88.72) .4896
95% CI 84.19,95.33 78.96e91.81 63.97e99.81 84.20e92.31
At least “better,” n (%) 68 (56.67) 62 (50.00) 4 (30.77) 134 (52.14) .1671
95% CI 47.31e65.68 40.89e59.11 9.09e61.43 45.84e58.39
No change or worse,
n (%)
11 (9.17) 17 (13.71) 1 (7.69) 29 (11.28)
e22 McMahon et alend point, whereas 45.7% of subjects with a baseline estimated
IELT of at least 1 minute achieved the composite end point at
study end (P ¼ .34; Table 4).
Satisfaction with intercourse. Overall, 73.8%, 86.3%, and
84.6% of subjects treated with dosages 1, 2, and 3, respectively,
were observed to achieve at least a one-category improvement in
satisfaction with intercourse at the ﬁnal visit (P ¼ .22; Table 4).Table 4. Summary of Efﬁcacy Results at Study End by Subgroup
Subgroup
CGIC at least “slightly
better,” n (%)
CGIC at lea
“better,” n
All subjects (n ¼ 278) 237 (85.25) 153 (55.04
Dosage group 1 (n ¼ 141) 109 (77.30) 77 (54.61)
Dosage group 2 (n ¼ 124) 115 (92.74) 70 (56.45)
Dosage group 3 (n ¼ 13) 13 (100.00) 6 (46.15)
Lifelong PE (n ¼ 115) 98 (85.22) 68 (59.13)
Acquired PE (n ¼ 163) 139 (85.28) 85 (52.15)
IELT < 1 min (n ¼ 138) 116 (84.06) 74 (53.62)
IELT > 1 min (n ¼ 140) 121 (86.43) 79 (56.43)
Total 237 (85.25) 153 (55.04
Last dose 60 mg 109 (77.30) 77 (54.61)
CGIC ¼ Clinical Global Impression of Change; IELT ¼ intravaginal ejaculation laOf those subjects with lifelong PE, 80.0% were observed to
achieve at least a one-category improvement in satisfaction with
intercourse, whereas 79.8% of subjects with acquired PE achieved
this response (P¼ .46). Of those subjects with a baseline estimated
IELT no longer than 1 minute, 77.5% were observed to achieve at
least a one-category improvement in satisfaction with intercourse,
whereas 82.1% of subjects with a baseline estimated IELT longer
than 1 minute achieved this response (P ¼ .99).st
(%)
Study end point
Control  2 and
distress  1, n (%)
Distress  1,
n (%)
Satisfaction  1,
n (%)
) 143 (51.44) 203 (73.02) 222 (79.86)
70 (49.65) 93 (65.96) 104 (73.76)
66 (53.23) 100 (80.65) 107 (86.29)
7 (53.85) 10 (76.92) 11 (84.62)
65 (56.52) 86 (74.78) 92 (80.00)
78 (47.85) 117 (71.78) 130 (79.75)
79 (57.25) 103 (74.64) 107 (77.54)
64 (45.71) 100 (71.43) 115 (82.14)
) 143 (51.44) 203 (73.02) 222 (79.86)
70 (49.65) 93 (65.96) 104 (73.76)
tency time; PE ¼ premature ejaculation.
Sex Med 2016;4:e18ee27
Table 5. Analysis of Factors Related to Clinical Global Impression
of Change Response with Logistic Regression
Variable Levels OR (95% CI) P value
Age Q1emedian 0.329 (0.088e1.236) .0997
medianeQ3 0.593 (0.141e2.501) .4770
Q3emaximum 4.840 (0.496. 47.237) .1749
Race Thai 699.320 (20.238e24,164.24) .0003
White 35.633 (2.428e522.860) .0091
Korean 17.198 (1.201e246.334) .0362
Other — —
PEDT 0.782 (0.244e2.512) .680
IELT 3.934 (1.024e15.113) .461
AE 0.312 (0.080e1.213) .0927
Dosage
group
30/ 60/
60 mg
1.483 (0.407e5.405) .5500
30/ 60/
30 mg
0.318 (0.057e1.767) .1906
AE ¼ adverse event; IELT ¼ intravaginal ejaculation latency time; OR ¼
odds ratio; PEDT ¼ Premature Ejaculation Diagnostic Tool; Q ¼ quartile.
The PASSION Study e23Personal distress. Overall, 66.0%, 80.1%, and 77.0% of
subjects treated with dosages 1, 2, and 3, respectively, were
observed to achieve at least a one-category decrease in distress
related to ejaculation at the ﬁnal visit (P ¼ .03; Table 4).
Of those subjects with lifelong PE, 74.8% were observed to
achieve at least a one-category decrease in distress related to
ejaculation, whereas 71.8% of subjects with acquired PE achieved
this response (P ¼ .62). Of those subjects with a baseline esti-
mated IELT no longer than 1 minute, 74.6% were observed to
achieve at least a one-category decrease in distress related to
ejaculation, whereas 71,4% of subjects with a baseline estimated
IELT longer than 1 minute achieved this response (P ¼ .81).
Interpersonal difﬁculty. There was no signiﬁcant difference
in interpersonal difﬁculty for each visit (from visit 2 to 5) among
subgroups of dosage (ie, 1, 2, or 3), PE type (ie, lifelong or
acquired), and baseline estimated IELT (ie, 1 or >1 minute),
except for a signiﬁcant difference (P ¼ .0012) between the
subgroup with a baseline estimated IELT no longer that 1
minute compared with those with a baseline estimated IELT
longer than 1 minute at visit 2.
Logistic regression failed to show any relation between any
change in the dosing of dapoxetine and potential factors
including demographics (age and race), IELT subgroup (esti-
mated baseline IELT  1 vs >1 minute), PEDT score, tolera-
bility (report of mild AE vs any moderate or severe AE), and
response to study drug (ie, CGIC rating of as least slightly better
vs no change or worse).
Logistic regression used to explore possible factors affecting
CGIC response demonstrated that the oldest group was signiﬁ-
cantly associated with CGIC response (odds ratio [OR] ¼
11.531, 95% CI ¼ 1.364e97.476) compared with the youngest
group. Compared with the Indian population, Thai, white, and
Korean subjects showed a signiﬁcant positive association with the
CGIC response (Table 5). The proportion of subjects describing
their PE as at least slightly better using the CGIC was statistically
signiﬁcantly lower for subjects who reported an AE of moderate
or severe severity compared with those who reported an AE of
mild severity.
The proportion of subjects CGIC rating their PE as at least
slightly better was statistically signiﬁcantly lower for subjects who
required an increase in the dose of dapoxetine to 60 mg and
maintained this dose compared with subjects who received only
30 mg throughout the duration of the study. Similar results were
shown for association with race. A larger proportion of subjects
with a baseline estimated IELT longer than 1 minute CGIC
rated their PE as at least slightly better compared with those with
a baseline estimated IELT shorter than 1 minute (OR ¼ 3.934,
95% CI ¼ 1.024e15.113).
Safety. AEs were reported by 134 subjects (47.69%), of whom
101 (37.59%) reported an AE related to study medicationSex Med 2016;4:e18ee27(Table 6). Thirteen subjects (4.63%) permanently discontinued
the study drug because of AEs, of which 10 (3.56%) reported an
AE considered related to the study drug. This group was
comprised of nine subjects (6.25%) treated with dosage 1 and
one subject (6.25%) treated with dosage 2. The most common
AE responsible for discontinuation was nausea (3, 1.07%), which
was limited to subjects treated with dosage 1. No subjects re-
ported syncope and two subjects reported serious AEs.
In total, 132 subjects (46.98%) reported treatment-emergency
AEs (TEAEs). The most commonly reported TEAEs were nausea
(n ¼ 38, 13.52%) and dizziness (n ¼ 32, 11.39%). These
TEAEs (nausea and dizziness) were more common in subjects
treated with dosage 3 than with dosage 1 or 2 (Table 6). Overall,
erectile dysfunction was reported by only 0.71% of subjects. In
general, most TEAEs were mild (Table 7). Three TEAEs related
to study medication were reported as severe (headache, n ¼ 2;
dizziness, n ¼ 1).
Two subjects had serious AEs. One subject treated with
dosage 1 developed severe dizziness, which was regarded as very
likely related to the study drug, and resolved the next day. The
other subject reported two events, including a road trafﬁc acci-
dent and facial bone fracture, which were severe and considered
not related to the study drug because no study drug was taken
before these events.DISCUSSION
PE PROs are psychometrically validated single-item diary
questions or multi-item multidomain questionnaires used as
diagnostic tools and intervention outcome measurements to
assess clinical improvement, intercourse-related subject and
partner sexual satisfaction, relationship satisfaction, personal
and interpersonal distress, and subject and partner quality of
Table 6. Treatment-Emergency Adverse Events in at Least 1% of Subjects by Preferred Term (Subgroups by Dosage)
Total patients, n (%)
Dosage 1 ¼ DPX 30 mg
(n ¼ 144)
Dosage 2 ¼ DPX 30/ 60 mg
(n ¼ 124)
Dosage 3 ¼ DPX
30/ 60/ 30 mg
(n ¼ 13)
Total
(n ¼ 281)
AE 47 (32.64) 47 (37.90) 10 (76.92) 104 (37.01)
Nausea 14 (9.72) 18 (14.52) 6 (46.15) 38 (13.52)
Dizziness 14 (9.72) 12 (9.68) 6 (46.15) 32 (11.39)
Headache 13 (9.03) 12 (9.68) 1 (7.69) 26 (9.25)
Somnolence 5 (3.47) 4 (3.23) 0 (0.00) 9 (3.20)
Dry mouth 3 (2.08) 4 (3.23) 0 (0.00) 7 (2.49)
Palpitations 4 (2.78) 3 (2.42) 0 (0.00) 7 (2.49)
Diarrhea 0 (0.00) 4 (3.23) 1 (7.69) 5 (1.78)
Fatigue 2 (1.39) 3 (2.42) 0 (0.00) 5 (1.78)
Hot ﬂush 3 (2.08) 1 (0.81) 0 (0.00) 4 (1.42)
Abdominal discomfort 0 (0.00) 3 (2.42) 0 (0.00) 3 (1.07)
Increased AST 3 (2.08) 0 (0.00) 0 (0.00) 3 (1.07)
Upper respiratory
tract infection
0 (0.00) 3 (2.42) 0 (0.00) 3 (1.07)
AE ¼ adverse effect; AST ¼ aspartate aminotransferase; DPX ¼ dapoxetine.
e24 McMahon et allife.30e32 PROs used in clinical trials of investigational drugs
should conform to the guidelines of the relevant regulatory
agency.36
Although PE PROs have been operationalized, they might not
be equally weighted, might vary in importance between subjects,
and might have different meanings in different cultures where
the attitude of the partner and culturally determined extent of
emancipation can have an impact on the subject’s subjective
diagnosis of PE. In the assessment of PE intervention outcomes
that capture changes to the multiple dimensions of PE such as
control, patient and partner bother, and other negative psycho-
logical effects and sexual satisfaction, the CGIC measurement is
often used to provide a clinically meaningful integrated summary
of an individual’s response to treatment.
Published clinical trial results have found that CGIC ratings
are sensitive to change in men with PE treated with
dapoxetine.21,24,29,37 In a post hoc analysis of 1,162 patients
from 22 countries who participated in a randomized, double-
blinded, parallel-group, placebo-controlled phase 3 trial of
dapoxetine, Althof et al30 assessed the validity and determinants
of the patient-reported CGIC rating of treatment response.
Althof et al reported that the IELT progressively increased for
each category of improvement on the CGIC: 1.63, 4.03, and
7.15 minutes for slightly better, better, and much better,Table 7. Treatment-Emergency Adverse Events by Severity (Subgrou
Adverse event
Dosage 1 ¼ 30 mg
(n ¼ 144)
Dosage 2 ¼ 30/ 6
(n ¼ 124)
Mild 53 (36.81) 53 (42.74)
Moderate 14 (9.72) 10 (8.06)
Severe 3 (2.08) 1 (0.81)
Total 63 (43.75) 57 (45.97)respectively. Similarly, higher CGIC ratings were correlated with
greater improvement in control (r ¼ 0.73), satisfaction (r ¼
0.62), greater decrease in distress (r ¼ 0.52), and interpersonal
difﬁculty (r ¼ 0.39). Total variance accounted for 57.4%:
control (48.7%), satisfaction (4.5%), IELT (2.8%), and distress
(1.15%). Althof et al concluded that the CGIC provides clini-
cians in practice with a valid and brief outcome assessment of
their patient’s response to intervention.
In this study, the use of a ﬂexible dosing regimen of dapox-
etine (30 and 60 mg) appeared effective in the treatment of Asia-
Paciﬁc men with PE. Using the CGIC, 85.3% of subjects
described their PE as at least slightly better at study end. This
included 77.3% of subjects who described their PE as at least
slightly better using the CGIC at visit 5 for subjects treated with
dosage 1, 92.4% treated with dosage 2, and 100% treated with
dosage 3.
Clinical efﬁcacy was comparable between subgroups for dis-
ease type (lifelong vs acquired PE) and IELT categories (1 vs
1 minute). The proportion of subjects who CGIC rated their
PE as at least slightly better was 85.3% among subjects with
lifelong PE and 85.2% among those with acquired PE. The
proportion of subjects who CGIC rated their PE as at least
slightly better was 84.1% among subjects with a baseline esti-
mated IELT no longer than 1 minute and 86.4% of those with aps by Dosage)
0 mg Dosage 3 ¼ 30/ 60/ 30 mg
(n ¼ 13)
Total
(n ¼ 281)
11 (84.62) 117 (41.64)
2 (15.38) 26 (9.25)
0 (0.00) 4 (1.42)
12 (92.31) 132 (46.98)
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among the three dosages was not signiﬁcant. In addition, 55.0%
of subjects described their PE as at least better using CGIC at
visit 5 (ﬁnal visit).
These results were comparable to, if not slightly better than,
previous global and regional Asia-Paciﬁc phase 3 trials and an inte-
grated analysis of pooled data from ﬁve phase 3 trials.21,24,25 In the
integrated analysis of pooled data from ﬁve phase 3 trials, a CGIC
rating of at least slightly better was reported at study end by 62.1%
and 71.7% of subjects using dapoxetine 30 and 60mg, respectively.
Furthermore, a CGIC rating of at least better was reported at study
end by 30.7% and 38.3% of subjects using dapoxetine 30 and
60 mg, respectively.29 In the Asia-Paciﬁc Study, McMahon et al24
reported a CGIC rating of at least slightly better in 71.4% and
79.2% of subjects treated with dapoxetine 30 and 60 mg, respec-
tively. Furthermore, a CGIC rating of at least better was reported at
study end by 37.4% and 41.5% of subjects with dapoxetine 30 and
60 mg, respectively. Similarly, Pryor et al21 reported a CGIC rating
of at least slightly better in 58% and 67% of subjects treated with
dapoxetine 30 and 60 mg, respectively.
Logistic regression showed that the incidence of a PE CGIC
rating of at least slightly better was lower in subjects who reported
an AE of moderate or severe severity compared with those who
reported an AE of mild severity and in subjects who required an
increase in the dose of dapoxetine to 60 mg and maintained this
dose compared with subjects who received only 30mg throughout
the duration of the study. Furthermore, logistic regression showed
a signiﬁcant and positive relation between a PE CGIC rating of at
least slightly better in Thai, Korean, and Caucasian subjects older
than 50 years (OR¼ 11.531) and a baseline estimated IELT longer
than 1 minute (OR ¼ 3.934).
The improvement in the composite end point of control over
ejaculation and distress, the satisfaction with sexual intercourse
end point, and the personal distress end point were similar
among those subjects treated with the three dosages, those with
lifelong vs acquired PE, and those with a baseline estimated
IELT no longer than vs longer than 1 minute. The differences
among all subgroups were not signiﬁcant.
The achievement of the composite end point of a two-category
improvement in control over ejaculation and a one-category
decrease in distress by 51.4% of subjects in this study exceeds
that reported in previous studies of similar subject populations.
In the Asia-Paciﬁc study, McMahon et al24 reported that treat-
ment with dapoxetine 30 and 60 mg achieved the composite end
point in 34.7% and 37.2% of subjects, respectively.
Similarly, 79.9% of all subjects achieved a greater than one-
category increase in satisfaction with sexual intercourse, and
73.0% of all subjects reported a greater than one-category
decrease in distress. This is comparable to or slightly exceeds
that reported by McMahon et al24 (satisfaction at 30 mg ¼
69.3%; satisfaction at 60 mg ¼ 75.9%; personal distress at 30
mg ¼ 66.6%; personal distress at 60 mg ¼ 72.7%).Sex Med 2016;4:e18ee27Previous studies have associated improvement in the com-
posite end point of control (greater than one-category improve-
ment in control and/or satisfaction) and distress (greater than
one-category decrease in distress) with a clinically signiﬁcant
fold increase in IELT.24 Although this study did not use patient-
estimated or stopwatch IELT as end points, the improvement
noted in the composite and single PROs suggests that subjects
achieved improvement in IELT.
This study showed that 84.1% and 86.4% of subjects with a
baseline IELT shorter than and longer than 1minute, respectively,
CGIC rated their PE as at least slightly better after treatment with
dapoxetine. Contrary to these ﬁndings, McMahon et al24 in the
Asia-Paciﬁc study reported that subjects with a baseline IELT
shorter than and longer than 1 minute had a lower CGIC rating of
at least slightly better after treatment (<1 minute with 30 mg ¼
69.9%; <1 minute with 60 mg ¼ 75.2%; >1 minute with 30
mg ¼ 72.7%; >1 minute with 60 mg ¼ 82.6%).
Dapoxetine was generally well tolerated in this study, which
used a ﬂexible-dosing regimen (30 and 60 mg). Reported AEs
were generally mild or moderate and there were no unexpected
or important new ﬁndings regarding the AE proﬁle of dapoxetine
or new safety concerns identiﬁed. The overall and individual
incidences of AEs were similar for dosages 1 and 2 and failed to
replicate the dose-related incidence seen in earlier phase 3
studies. The reason for this is unclear but probably reﬂects the
observation that AEs often attenuate and resolve with continued
drug usage. The incidence of AEs was higher with dosage 3,
which could reﬂect the option of the subject to decrease the
dapoxetine dose from 60 to 30 mg owing to intolerable AEs.
This study is limited by the lack of a blinded placebo or active
comparator arm. Some degree of subject and/or investigator bias
could have inﬂuenced the results. The lack of validation of the
PEDT, PEP, and CGIC in non-English Asia-Paciﬁc languages
before the commencement of study is regarded by the authors as
a potential but minor limitation of this study. In addition, the
lack of IELT data after dapoxetine treatment might be consid-
ered another potential limitation when comparing data from this
study to those of the dapoxetine phase 3 registration program.
The sample size could limit the detection of infrequent AEs.CONCLUSIONS
Consistent with results from previous phase 3 studies, dapox-
etine 30 and 60 mg as needed signiﬁcantly improved the CGIC
rating of PE, the composite responder end point of at least a two-
category improvement in control over ejaculation, and at least a
one-category decrease in distress related to ejaculation and the
individual PRO end points of ejaculatory control, satisfaction with
sexual intercourse, personal distress, and interpersonal distress.
Clinical efﬁcacy was comparable between subgroups for disease
type (lifelong vs acquired PE) and IELT categories (1 vs 1
minute). Dapoxetine was well tolerated and TEAEs were mild.
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